EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing Venetoclax Dosing and Treatment Duration with Azacitidine in Acute Myeloid Leukemia: Evidence, Limitations, and Personalized Strategies

Matteo Molica, Laura De Fazio, Martina Costa, Giulio Caridà, Antonino Mulè, Ferdinando Porretto, Caterina Alati, Massimo Martino, Marco Rossi

Cancers · 13.11.2026 · 18 (22) · 3625

DOI: 10.3390/cancers18223625 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 13.11.2026. Verfasst von Matteo Molica und 8 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venetoclax combined with azacitidine has transformed the treatment of newly diagnosed acute myeloid leukemia in patients ineligible for intensive chemotherapy. However, prolonged cytopenias, infectious complications, and treatment interruptions have prompted increasing use of abbreviated venetoclax schedules. This narrative review critically examines the evidence supporting modifications in treatment duration and daily dose, with emphasis on the balance between antileukemic efficacy and tolerability. Retrospective studies, including the analysis by Willekens and colleagues, suggest that shorter schedules may reduce selected measures of hematologic toxicity and supportive-care burden while maintaining encouraging remission rates. Nevertheless, these findings are vulnerable to selection bias and cannot establish equivalence. Importantly, the randomized OPTI-AML trial did not demonstrate noninferiority of a 14-day induction schedule compared with 28 days and identified a potentially relevant reduction in early complete remission among patients harboring NPM1 and/or IDH2 mutations. These observations suggest that the consequences of shortening venetoclax exposure may depend on treatment phase and leukemia biology. We discuss pharmacokinetic interactions, post-remission cytopenia management, and molecularly informed treatment adaptation, and highlight the need for prospective studies that jointly evaluate efficacy, toxicity, and patient-centered outcomes.

Zitieren

APA

Molica, M., Fazio, L. D., Costa, M., Caridà, G., Mulè, A., Porretto, F., Alati, C., Martino, M., & Rossi, M. (2026). Optimizing Venetoclax Dosing and Treatment Duration with Azacitidine in Acute Myeloid Leukemia: Evidence, Limitations, and Personalized Strategies. Cancers, 18(22), 3625. https://doi.org/10.3390/cancers18223625

Vancouver

Molica M, Fazio LD, Costa M, Caridà G, Mulè A, Porretto F, et al. Optimizing Venetoclax Dosing and Treatment Duration with Azacitidine in Acute Myeloid Leukemia: Evidence, Limitations, and Personalized Strategies. Cancers. 2026;18(22):3625. doi:10.3390/cancers18223625

BibTeX
@article{Molica2026,
  author = {Molica, Matteo and Fazio, Laura De and Costa, Martina and Caridà, Giulio and Mulè, Antonino and Porretto, Ferdinando and Alati, Caterina and Martino, Massimo and Rossi, Marco},
  title = {Optimizing Venetoclax Dosing and Treatment Duration with Azacitidine in Acute Myeloid Leukemia: Evidence, Limitations, and Personalized Strategies},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3625},
  doi = {10.3390/cancers18223625}
}
Kostenlos starten →